RefleXion Medical has signed a non-exclusive, worldwide licensing agreement with Mirada Medical to advance personalised cancer treatment.

Under the terms of the deal, Mirada’s RegEngine image registration algorithms will be integrated into the RefleXion X1 treatment planning software.

The RegEngine algorithms align patient anatomy between various imaging approaches or radiotherapy treatments.

In radiation oncology millimetres matter in the protection of healthy tissue, so it is critical to have registration of the tumour target to be treated as well as nearby anatomy.

The registration of images involves a complex set of algorithms that align the anatomy pictures of a patient obtained at various times using different imaging techniques.

According to the company, accurate targeting may lead to reducing toxicity and improving patient outcomes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

RefleXion chief business officer Thorsten Melcher said: “Day-of-treatment modifications, called adaptive radiotherapy, are critical for responding to changes in patient anatomy that occur as a result of cancer treatment, and to lowering toxicity to improve outcomes.

“In challenging patients, such as those with metastatic disease, where more than one tumour may be treated, adaptation requires robust tools, such as Mirada’s sophisticated RegEngine software, so that clinicians can quickly assess patient anatomy and, in the future their biology, to implement changes to the treatment plan.”

Biology-guided radiotherapy (BgRT) is intended to one day overcome the technological limits of current radiation treatments by using a positron emission tomography (PET) radiotracer to create a unified motion management system for either one or several tumours.

Using real-time biological data, BgRT delivers a tracked radiation dosage to the cancer.

The integration of RegEngine into BgRT enables accurate registration of pictures and image components necessary for treatment planning and dosage calculation.

RegEngine warps or deforms the images pixel by pixel to help clinicians understand the changes and allow them to quickly modify the daily treatment plan.